BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development
News
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
FDA approves ANDA of 20mg generic Nitisinone capsules
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Lonza to acquire Synaffix to strengthen ADC development
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
Sanofi announces positive data for frexalimab in relapsing MS
The neurological disease affects approximately 2.8 million people worldwide
Amgen’s Otezla shows promise in psoriatic arthritis
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
EU regulator recommends revoking approval for Novartis’ sickle cell disease drug
The EMA’s human medicines committee concluded that the benefits of Adakveo did not outweigh its risks
AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
The drug has already been approved for this indication in the EU, with regulatory reviews continuing elsewhere including in the US
Positive opinion for Novo Nordisk’s Sogroya
Therapy has been developed for use among children and adolescents with growth hormone deficiency
Delivery pivotal as UK life sciences plan takes shape
Life Sciences Council meeting hosted by chancellor Jeremy Hunt has unfolded in Downing Street
Centre for Genomic Regulation and Almirall join forces on skin cancer treatments
The collaboration aims to develop novel preclinical models with a view to identifying new treatments
BioInvent and Transgene and report positive BT-001 data
Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns
Celadon secures medicinal cannabis contract
Celadon will sell a minimum of £3m worth of the high-THC product over the next three years
AstraZeneca provide further Breztri evidence
Vital data supports early intervention in order to treat chronic obstructive pulmonary disease
Scarlet Therapeutics gains funding for blood cell platform
Vital financing will allow the company to build a pipeline of novel therapies targeting serious conditions
